Kairos Pharma, Ltd.

KAPA

Healthcare|Biotechnology|US

$0.49

+0.03 (+7.33%)

DCF Value

$1.64

Tangible Book / Share

$1.37

Cash / Share

$0.86

About

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.

Stock Price

-92.0%(1Y)

-49.2%

-81.9%

-87.6%

YTD

-90.2%

-92.5%

-97.3%

Pipeline Summary

2 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Withdrawn: 1Recruiting: 1

Active Trials (1)

Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

NCT05534646Castration-resistant Prostate Cancer

Phase 2Recruiting

Enrollment: 116 participants

Key Facts

Market Cap$1.7M

Employees1 (+0% YoY)

CEOJohn S. Yu

IPO DateSep 16, 2024

Beta1.44

52-Week Range$0.418 – $7.28

Avg Volume477,198

ExchangeAMEX

Websitekairospharma.com

Ownership

Float41.9%

Shares Outstanding3.4M

Recent Insider Trades

Bhowmick NeilAWARD

Oct 8, 2025171,756 shares

Bae Hyun W.AWARD

Oct 8, 202519,084 shares

Bae Hyun W.AWARD

Sep 16, 202510,000 shares

Murali RamachandranAWARD

Oct 8, 2025152,672 shares

Keyoung Hansoo MichaelAWARD

Oct 8, 202519,084 shares

Peers

ALLRAllarity Therapeutics, Inc.

$15.4M

BCTXBriaCell Therapeutics Corp.

$34.5M

CASICASI Pharmaceuticals, Inc.

$3.1M

CINGCingulate Inc.

$61.9M

CLSDClearside Biomedical, Inc.

$2.1M

ENTOEntero Therapeutics, Inc.

$13.6M

LEXXLexaria Bioscience Corp.

$7.4M

LIXTLixte Biotechnology Holdings, Inc.

$89.1M

Recent News

Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology

Nov 5, 2026 · businesswire.com

Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development

Nov 3, 2026 · businesswire.com

CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma

Oct 22, 2026 · newsfilecorp.com

Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer

Oct 6, 2026 · benzinga.com

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Oct 6, 2026 · businesswire.com

Data last updated: Nov 9, 2026, 04:17 AM